VSSP-activated macrophages mediate senescence and tumor inhibition in a preclinical model of advanced prostate cancer.
Adoptive transfer
Macrophages
Prostate cancer
VSSP
Journal
Cell communication and signaling : CCS
ISSN: 1478-811X
Titre abrégé: Cell Commun Signal
Pays: England
ID NLM: 101170464
Informations de publication
Date de publication:
13 04 2023
13 04 2023
Historique:
received:
18
11
2022
accepted:
07
03
2023
medline:
17
4
2023
entrez:
13
4
2023
pubmed:
14
4
2023
Statut:
epublish
Résumé
Androgen deprivation therapy (ADT) is a standard therapy for prostate cancer (PCa). Though disseminated disease is initially sensitive to ADT, an important fraction of the patients progresses to castration-resistant prostate cancer (CRPC). For this reason, the identification of novel effective therapies for treating CRPC is needed. Immunotherapeutic strategies focused on macrophages as antitumor effectors, directly enhancing their tumoricidal potential at the tumor microenvironment or their adoptive transfer after ex vivo activation, have arisen as promising therapies in several cancer types. Despite several approaches centered on the activation of tumor-associated macrophages (TAMs) in PCa are under investigation, to date there is no evidence of clinical benefit in patients. In addition, the evidence of the effectiveness of macrophage adoptive transfer on PCa is poor. Here we find that VSSP, an immunomodulator of the myeloid system, decreases TAMs and inhibits prostatic tumor growth when administered to castrated Pten-deficient prostate tumor-bearing mice. In mice bearing castration-resistant Pten
Identifiants
pubmed: 37055829
doi: 10.1186/s12964-023-01095-3
pii: 10.1186/s12964-023-01095-3
pmc: PMC10100133
doi:
Substances chimiques
Androgen Antagonists
0
Types de publication
Video-Audio Media
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
76Informations de copyright
© 2023. The Author(s).
Références
Prostate Cancer Prostatic Dis. 2019 Sep;22(3):420-427
pubmed: 30643173
J Immunother Cancer. 2019 Aug 14;7(1):218
pubmed: 31412954
Cell Mol Life Sci. 2015 Nov;72(21):4111-26
pubmed: 26210152
Oncotarget. 2015 Oct 27;6(33):34221-7
pubmed: 26439694
Cancers (Basel). 2022 Jan 16;14(2):
pubmed: 35053602
Vaccine. 2004 Aug 13;22(23-24):3045-52
pubmed: 15297054
Trends Immunol. 2002 Nov;23(11):549-55
pubmed: 12401408
Eur J Immunol. 2007 Jan;37(1):14-6
pubmed: 17183610
Cell Rep. 2019 Aug 20;28(8):2156-2168.e5
pubmed: 31433989
Curr Opin Immunol. 2010 Apr;22(2):231-7
pubmed: 20144856
Nature. 2018 Jul;559(7714):363-369
pubmed: 29950727
Cancer Lett. 2022 Feb 1;526:304-310
pubmed: 34863887
J Control Release. 2016 Oct 28;240:527-540
pubmed: 27422609
Vaccine. 2006 Mar 24;24(14):2692-9
pubmed: 16316710
Cancer Res. 2021 Mar 1;81(5):1201-1208
pubmed: 33203697
Semin Oncol. 2018 Jan;45(1-2):84-94
pubmed: 30318088
Front Immunol. 2016 Feb 10;7:32
pubmed: 26904023
Vaccine. 2012 Apr 19;30(19):2963-72
pubmed: 22391399
Cancer Stud Ther. 2019 Sep;4(4):
pubmed: 32148662
Nature. 2005 Aug 4;436(7051):725-30
pubmed: 16079851
J Immunol. 2011 Jan 1;186(1):264-74
pubmed: 21135171
Cancer Immunol Immunother. 2022 Oct;71(10):2355-2369
pubmed: 35166871
Am J Cancer Res. 2011;1(1):120-127
pubmed: 21969236
J Clin Invest. 2010 Mar;120(3):681-93
pubmed: 20197621
Vaccine. 1999 Aug 20;18(1-2):190-7
pubmed: 10501249
J Immunother Cancer. 2014 Mar 11;2:5
pubmed: 24829762
Front Med (Lausanne). 2020 Nov 05;7:583708
pubmed: 33251232
Vaccine. 2006 Apr 12;24 Suppl 2:S2-42-3
pubmed: 16823920
Clin Cancer Res. 2014 Aug 15;20(16):4262-73
pubmed: 24919573